{"id":"NCT01464190","sponsor":"Vifor Pharma","briefTitle":"A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients","officialTitle":"An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Phase 3 Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21 Compared With Sevelamer Carbonate in Dialysis Patients With Hyperphosphataemia. Extension Study for Protocol PA-CL-05A (NCT01324128)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2012-10","completion":"2013-04","firstPosted":"2011-11-03","resultsPosted":"2014-02-17","lastUpdate":"2014-04-01"},"enrollment":659,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Kidney Disease Requiring Chronic Dialysis"],"interventions":[{"type":"DRUG","name":"PA21 (2.5 g tablet containing 500 mg iron)","otherNames":[]},{"type":"DRUG","name":"Sevelamer carbonate","otherNames":[]}],"arms":[{"label":"PA21","type":"EXPERIMENTAL"},{"label":"Sevelamer carbonate","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase 3, randomised, active controlled, multicentre extension study to investigate the long-term safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients. This is an extension study to PA-CL-05A (NCT01324128), subjects have already been enrolled and have been treated with study medication for at least 24 weeks.","primaryOutcome":{"measure":"Change From Baseline and Levels at Each Time Point for Serum Phosphorus","timeFrame":"Every 4 weeks from baseline to Week 28","effectByArm":[{"arm":"PA21","deltaMin":-0.2,"sd":1.33},{"arm":"Sevelamer Carbonate","deltaMin":-0.1,"sd":1.47}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":15,"countries":["United States","Austria","Belgium","Croatia","Czechia","Germany","Latvia","Lithuania","Poland","Romania","Russia","Serbia","South Africa","Ukraine","United Kingdom"]},"refs":{"pmids":["40576086","29656600"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":78,"n":391},"commonTop":["Hyperphosphataemia","Hypertension","Diarrhoea","Muscle spasms","Hypotension"]}}